Search / Trial NCT06232967

PPIO-006 Primary Tumor Resection for IVa NSCLC

Launched by DAPING HOSPITAL AND THE RESEARCH INSTITUTE OF SURGERY OF THE THIRD MILITARY MEDICAL UNIVERSITY · Jan 22, 2024

Trial Information

Current as of December 30, 2024

Completed

Keywords

ClinConnect Summary

Non-small-cell lung cancer (NSCLC) patients with dry pleural dissemination have poor survival rates and are generally contraindicated for surgery. Previous single-center retrospective studies have suggested that these patients may benefit from primary tumor resection (PTR). However, the evidence supporting PTR is still limited, especially in the era of targeted therapy. This study aimed to investigate the impact of PTR on the long-term survival of patients with NSCLC and DPD.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • (1) pathologically confirmed primary NSCLC with malignant pleural dissemination, (2) no preoperative treatment, (3) age 80 years or younger, (4) clinicopathologic data and follow-up results were complete.
  • Exclusion Criteria:
  • (1) pleural effusion, contralateral lung metastasis or distant metastasis revealed preoperatively, and (2) with a history of other malignant disease.

Trial Officials

Wei Guo, PhD

Principal Investigator

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

About Daping Hospital And The Research Institute Of Surgery Of The Third Military Medical University

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University is a leading clinical trial sponsor dedicated to advancing medical research and improving patient outcomes. Renowned for its innovative approach to surgical and medical research, the institution combines cutting-edge technology with a team of experienced clinicians and researchers to conduct rigorous clinical trials. With a commitment to ethical standards and patient safety, Daping Hospital aims to translate scientific discoveries into effective therapeutic interventions, contributing significantly to the global medical community.

Locations

Chongqing, Chongqing, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0